Boehringer Ingelheim Venture Fund
◆ Fund Size
$114.4M
◆ Check Size
◆ Location
Germany
◆ Links
◆ Share this fund
◆ Investment Thesis
To foster innovation in life sciences through corporate venture capital investments.
◆ About Boehringer Ingelheim
The Boehringer Ingelheim Venture Fund (BIVF), established in 2010, is a €350M evergreen corporate venture fund that invests in first-in-class, disease-modifying therapeutics across various modalities, focusing on groundbreaking innovation in cancer (immuno-oncology & targeted therapy), regenerative medicine, auto-immunity, digital solutions, and infectious diseases (AMR).[1][2][6] It primarily targets pre-clinical assets and platforms as a dedicated Seed/Series A investor, with global presence in the EU, US, and China, taking minority stakes and board seats to actively support portfolio companies aligned with Boehringer Ingelheim's strategic interests.[1][2][5]
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Boehringer Ingelheim Venture Fund invest in?
Boehringer Ingelheim Venture Fund invests in Biotech, Drug Discovery, Digital Health, Medtech and Diagnostics at the seed and series-a stages.
Which geographies does Boehringer Ingelheim Venture Fund focus on?
Boehringer Ingelheim Venture Fund focuses on Global, and is headquartered in Germany.
What is Boehringer Ingelheim Venture Fund's typical check size?
Boehringer Ingelheim Venture Fund typically writes checks of $3M to $15M.